Therapeutic effect of dual oral therapy with daclatasvir and asunaprevir for choronic HCV patient with depression

DOI Web Site Web Site 4 References Open Access
  • Takeda Kosuke
    Third Department of Internal Medicine, Nara Medical University
  • Noguchi Ryuichi
    Third Department of Internal Medicine, Nara Medical University Gut & Liver Center, Heisei Memorial Hospital
  • Namisaki Tadashi
    Third Department of Internal Medicine, Nara Medical University
  • Moriya Kei
    Third Department of Internal Medicine, Nara Medical University
  • Mashitani Tuyoshi
    Third Department of Internal Medicine, Nara Medical University
  • Kitade Mituteru
    Third Department of Internal Medicine, Nara Medical University
  • Kawaratani Hideto
    Third Department of Internal Medicine, Nara Medical University
  • Okura Yasushi
    Third Department of Internal Medicine, Nara Medical University
  • Kaji Kosuke
    Third Department of Internal Medicine, Nara Medical University
  • Aihara Yosuke
    Gastroenterology, Nara Prefecture General Medical Center
  • Nishimura Norihisa
    Third Department of Internal Medicine, Nara Medical University
  • Sawada Yasuhiko
    Third Department of Internal Medicine, Nara Medical University
  • Satou Shinya
    Third Department of Internal Medicine, Nara Medical University
  • Seki Kenitirou
    Third Department of Internal Medicine, Nara Medical University
  • Mitoro Akira
    Third Department of Internal Medicine, Nara Medical University
  • Yoshiji Hitoshi
    Third Department of Internal Medicine, Nara Medical University

Bibliographic Information

Other Title
  • ダクラタスビル・アスナプレビル併用療法の抑うつに及ぼす影響
  • ダクラタスビル ・ アスナプレビル ヘイヨウ リョウホウ ノ ヨクウツ ニ オヨボス エイキョウ

Search this article

Description

<p>In this study, we compared the severity of depression in HCV-patients treated with Interferon (IFN) or with daclatasvir (DCV) plus asunaprevir (ASV). Analysis of Beck Depression Inventory-Second Edition (BDI)-II score showed that the patient with IFN therapy exerted significantly increased scores indicating depression states. In contrast, the patient with DCV/ASV showed decreased BDI score. However, in patients with high BDI score before DCV/ASV dual therapy tendered to increase depressive states at four weeks after treatment, which were recovered at the end of treatment at twelve weeks. We may need careful correspondence including consult to psychiatry with the early detection of the depressive symptoms using BDI.</p><p>In summary, DCV/ASV dual therapy does not induce depression except on the patients with depression.</p>

Journal

  • Kanzo

    Kanzo 57 (9), 496-498, 2016

    The Japan Society of Hepatology

References(4)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top